Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cognivue Clarity characterizes mild cognitive impairment and Alzheimer’s disease in biomarker confirmed cohorts in the Bio-Hermes Study

18 Oct 2024

Abstract excerpt

The Bio-Hermes Study was a cross-sectional observational study designed to develop a database of blood-based and digital biomarkers to improve detection of Alzheimer's disease (AD) and mild cognitive impairment (MCI). We examined the ability of Cognivue Clarity to (a) detect MCI and AD in clinical diagnostics groups, (b) determine the presence of amyloid, and (c) distinguish between biomarker-confirmed groups....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Dementia and Cognitive Impairment Research
Share to Health, Environment, Cognitive Aging
Share to Nutritional Studies and Diet

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39424626
DOI: 10.1038/s41598-024-75304-5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cognivue Clarity characterizes mild cognitive impairment and Alzheimer’s disease in biomarker confirmed cohorts in the Bio-Hermes StudyPMID 39424626Read ↗

Validation of the self-test computerised PROTECT Cognitive Test System for detection of dementia and Mild Cognitive ImpairmentSemantic proximity Read ↗

The Bio‐Hermes Study: Biomarker database developed to investigate blood‐based and digital biomarkers in community‐based, diverse populations clinically screened for Alzheimer's diseaseSemantic proximity Read ↗

Concurrent Detection of Cognitive Impairment and Amyloid Positivity with a Next-Generation Digital Cognitive AssessmentSemantic proximity Read ↗

Comprehensive evaluation of AT(N) imaging biomarkers for predicting cognitionSemantic proximity Read ↗

A FinnGen pilot clinical recall study for Alzheimer’s diseaseSemantic proximity Read ↗

The CentiMarker project: Standardizing quantitative Alzheimer's disease fluid biomarkers for biologic interpretationSemantic proximity Read ↗

Predicting 24-Month MCI-to-Alzheimer’s Conversion Using Routine Clinical Assessments Without Neuroimaging or Genetic TestingSemantic proximity Read ↗

Bloodwork-free Early Screening for Alzheimer’s Disease via Comorbid Pattern Recognition in Electronic Health RecordsSemantic proximity Read ↗

The Ignite app detects early cognitive impairment and tracks disease severity in genetic frontotemporal dementiaSemantic proximity Read ↗

Multimodal Imaging and Logistic Weighted Cognitive Scores for Classification of MCI, AD, and FTD SubtypesSemantic proximity Read ↗

Scalable Markers for Early Cognitive Decline: Plasma p-tau217, Subjective Cognitive Concerns, and Digital Testing: Results from the A4/LEARN studiesSemantic proximity Read ↗

AT(N) predicts near-term development of Alzheimer’s disease symptoms in unimpaired older adultsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.